Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 Current Ratio is 2.01 as of Mar. 2026, which is 47% above its 10-year median of 1.37. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 999 Drug Manufacturers companies, Rubicon Research ranks better than 50.75% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Rubicon Research's current ratio for the quarter that ended in Mar. 2026 was 2.01.
Rubicon Research has a current ratio of 2.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for Rubicon Research's Current Ratio or its related term are showing as below:
NSE:RUBICON'
s Current Ratio Range Over the Past 10 Years
Min: 1.33 Med: 1.37 Max: 2.01
Current: 2.01
During the past 4 years, Rubicon Research's highest Current Ratio was 2.01. The lowest was 1.33. And the median was 1.37.
NSE:RUBICON's Current Ratio is ranked better than 50.75% of 999
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:RUBICON: 2.01
Rubicon Research (NSE:RUBICON) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Rubicon Research Current Ratio Related Terms
Rubicon Research Current Ratio Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Current Ratio distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a Current Ratio of 2.01 as of Mar. 2026. This is 47% above median its historical median of 1.37. Over the past decade, Rubicon Research's Current Ratio has ranged from 1.33 to 2.01. According to the industry distribution chart, Rubicon Research ranks #492 out of 999 companies in the Drug Manufacturers industry, placing it in the top 49.2%.
Is Rubicon Research's Current Ratio too high?
Rubicon Research's current Current Ratio of 2.01 is 47% above median its 10-year median of 1.37. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 2.01. The Drug Manufacturers industry median Current Ratio is 2.00. Rubicon Research's value of 2.01 is 0.5% above this industry median. Based on the distribution chart, Rubicon Research ranks #492 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #492 out of 999 companies for Current Ratio. This puts Rubicon Research in the upper half of its industry. The industry median Current Ratio is 2.00. Rubicon Research's value of 2.01 is 0.5% above this benchmark. Historically, Rubicon Research's own Current Ratio has ranged from 1.33 to 2.01 over the past decade. While the company's 10-year median is 1.37 vs. the industry median of 2.00, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current Current Ratio of 2.01 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Current Ratio is 2.01, which is 47% above median its own 10-year median of 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Current Ratio of 2.01. The current Current Ratio is 2.01, which is 47% above median its 10-year median of 1.37 and 0.5% above the Drug Manufacturers industry median of 2.00. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Current Ratio is 2.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
